Lifastuzumab vedotin

Catalog No.D4010        Batch: D401001

Print

Technical Data

CAS No. 1401812-88-1
Formulation 0.1 MPro-Ac,0.02 MArg-Ac,pH5.0
ADC antiody Lifastuzumab
ADC cytotoxin MMAE
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Purity 99%
Protein concentration 8.79mg/ml
Endotoxin Level <1EU/mg

Biological Activity

Description Lifastuzumab vedotin (LIFA, DNIB0600A, RG-7599) is an antibody-drug conjugate (ADC) composed of a humanized anti-NaPi2b monoclonal antibody and an anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE) . Lifastuzumab vedotin is used in the treatment of platinum-resistant ovarian cancer.

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.